Valneva Austria GmbH

Founded

2013

Staff

212

Organization type

RDM biotech/pharma

Region

Vienna

Cluster

LISAvienna

Focus

human health

Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. We have leveraged our expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.

R&D:We take a highly specialized and targeted approach to vaccine development, beginning with the identification of deadly and debilitating infectious diseases that lack a prophylactic vaccine solution and for which there are limited therapeutic treatment options. We then apply our deep understanding of vaccine science, including our expertise across multiple vaccine modalities, as well as our established vaccine development capabilities, to develop prophylactic vaccines to address these diseases.

Production:Our manufacturing base provides a long-term and sustainable industrial network to supply clinical trial material and commercial products based on objectives for delivery schedule, costs, flexibility and quality. We operate three manufacturing sites augmented by contract manufacturing partners. Our manufacturing network has been operating and producing licensed vaccines for more than 10 years. We have a highly experienced management team and workforce operating our production network.

Services:Valneva also leverages its capabilities in product development and clinical trial materials manufacturing with third parties by providing the following services: Technical development, Clinical immunology assay development and sample testing services, Clinical manufacturing, In vivo testing for preclinical proof of concept (PoC), immunogenicity and safety assessments, General facility services, Clinical strategy and operations for clinical-stage vaccine programs.

Sales/Distribution:Sales of commercial vaccines were were €65.9 million in 2020, impacted by COVID-19 related consequences on the travel market. Valneva's 2020 total revenues were €110.3 million.